Zymeworks (NASDAQ:ZYME) Given New $46.00 Price Target at HC Wainwright

Zymeworks (NASDAQ:ZYME) had its price target hoisted by HC Wainwright from $32.00 to $46.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently issued reports on ZYME. B. Riley Financial reissued a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Zymeworks in a research report on Friday, November 21st. Leerink Partners lifted their price objective on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday. Truist Financial started coverage on shares of Zymeworks in a research report on Wednesday, December 17th. They set a “buy” rating and a $40.00 target price for the company. Wells Fargo & Company upgraded shares of Zymeworks from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $25.00 to $33.00 in a report on Friday, December 12th. Finally, Citigroup assumed coverage on shares of Zymeworks in a research report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.10.

Zymeworks Price Performance

Shares of ZYME stock opened at $24.08 on Friday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $28.49. The firm’s 50-day simple moving average is $23.72 and its 200-day simple moving average is $21.08. The firm has a market cap of $1.78 billion, a P/E ratio of -22.30 and a beta of 1.23.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $21.78 million. Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The business’s revenue for the quarter was down 91.9% on a year-over-year basis. During the same period last year, the company posted ($0.31) EPS.

Insider Activity

In other news, EVP Jeffrey T. L. Smith sold 10,538 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, for a total transaction of $264,503.80. Following the transaction, the executive vice president directly owned 18,352 shares of the company’s stock, valued at approximately $460,635.20. The trade was a 36.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kenneth Galbraith sold 54,343 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, for a total transaction of $1,364,009.30. Following the sale, the chief executive officer directly owned 158,286 shares of the company’s stock, valued at approximately $3,972,978.60. The trade was a 25.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 187,933 shares of company stock valued at $4,673,716. 33.51% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zymeworks

Hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Zymeworks in the 4th quarter valued at approximately $37,000. Optiver Holding B.V. acquired a new stake in shares of Zymeworks during the third quarter worth approximately $26,000. Quarry LP acquired a new stake in shares of Zymeworks during the third quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Zymeworks by 25.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock worth $96,000 after buying an additional 731 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Zymeworks by 29.6% in the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after acquiring an additional 1,131 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $46 and reiterated a Buy rating — the new target implies substantial upside from current levels. Benzinga
• Positive Sentiment: Stifel Nicolaus boosted its price target to $47, another significant upward revision that supports a bullish view on ZYME’s longer‑term recovery. Stifel Target
• Positive Sentiment: Leerink Partners published a bullish forecast for Zymeworks, contributing to the cluster of upgrades and positive analyst sentiment this week. Leerink Report
• Neutral Sentiment: Lifesci Capital updated its FY-2026 and quarterly EPS forecasts with mixed changes: it materially improved the FY-2026 loss estimate (from -$1.40 to -$0.68) and sharply raised Q2/Q3 outlooks, but it lowered the Q1 estimate — a mixed signal that improves multi‑quarter visibility while acknowledging near‑term pressure. Lifesci Estimates
• Negative Sentiment: Recent quarterly results (reported March 2) showed a meaningful EPS miss and a ~92% YoY revenue decline, leaving Zymeworks unprofitable with negative margins — fundamentals that likely temper enthusiasm and explain part of the intraday weakness despite upgrades. Earnings Detail

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.